News Category
Quantum BioPharma is advancing a diversified strategy that combines clinical drug development, consumer wellness, and royalty-based partnerships to ad...
PolyPeptide shareholders approved a new board and the removal of transfer restrictions and voting limits, clearing key conditions for Samsung Biologic...
The UK's MHRA has issued new safety measures for antidepressants, including broader suicide-risk warnings and recognition of persistent sexual dysfunc...
Cotecna's acquisition of Energon Labs strengthens its global life sciences platform and expands pharmaceutical testing capabilities in India, a key gr...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced that its subsidiary MindWave Innovations' NILA token will list on Pionex exchange on ...
Nutriband's $1.75 million warrant exercise proceeds will fund the clinical development and FDA submission for its abuse-deterrent fentanyl patch, pote...
DuLac Farmaceutici is advancing U.S. retail growth by following up with partners after the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Ses...
Nutriband Inc. has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating methods that could...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to reduce animal testing in preclinical research, potentially accelerating clini...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter from CEO Gareth Sheridan detailing the advancem...
Helus Pharma's legal name change from Cybin Inc. signals its shift from a clinical-stage discovery company to a commercial-ready pharmaceutical compan...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate beyond discovery, planning final engineering and preclinical studies, while ex...
Apimeds Pharmaceuticals US subsidiary MindWave Innovations will develop and operate FlashChain, a blockchain for tracking digital broadcasting rights ...
Creative Biolabs connects glycoprotein development with glycan characterization to help researchers manage glycosylation-driven heterogeneity and make...
Helus Pharma shareholders approved a legal name change from Cybin Inc. to Helus Pharma Inc. and elected eight directors, signaling the company's trans...
Nutriband Inc. (NASDAQ: NTRB) will let its 910,904 outstanding warrants expire on September 30, 2026, without extension or repricing, potentially forg...
Peptide Wholesale Supply now provides HPLC chromatographic data for every batch of BPC-157, Semaglutide, and Tirzepatide in bulk orders, enhancing ana...
Telomir Pharmaceuticals' Telomir-Zn inhibits growth in human and canine osteosarcoma cell lines, suggesting a potential translational pathway for both...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's lead candidate ENV-105, which targets CD105 to reverse dru...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step for a novel myelin-repair approach in multiple sclerosis, drawing an...
Nutriband received a USPTO Notice of Publication for trademarks related to its abuse-deterrent fentanyl patch, moving closer to commercial launch and ...
Quantum BioPharma's multiple sclerosis drug candidate Lucid-MS has drawn a 'Buy' rating and an $8.00 price target from Rodman & Renshaw, underscoring ...
Earth Science Tech's acquisition of Zoolzy LLC enhances its compounding pharmacy operations by providing competitive wholesale access to APIs and FDA-...
Italian pharmaceutical company DuLac Farmaceutici is broadening its U.S. presence through a new e-commerce channel and retail buyer meetings, signalin...
Retatrutide, a weight loss drug not FDA-approved, is being illegally sold online, leading to increased poison control reports and hospitalizations, pr...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into the next development stage after completing the initial OmniAb co...
Onco-Innovations has signed a letter of intent to obtain an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, potentially co...
Earth Science Tech's acquisition of Zoolzy LLC is poised to enhance its compounding pharmacy margins and enable entry into the veterinary therapeutics...
SCHOTT Pharma's parent group has updated its climate targets, validated by the SBTi, introducing an absolute Scope 3 reduction target to drive value-c...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is progressing with enrollment complete and topline data expected in Q4 2026, w...
VERAXA Biotech's VXA-222 bispecific ADC program moves past discovery, and the company expands its IP estate with new patent filings, strengthening its...
Tonix Pharmaceuticals announced FDA feedback supporting its planned adaptive Phase 2 field study for TNX-4800, a long-acting monoclonal antibody for L...
VERAXA Biotech announced the advancement of its bispecific ADC program VXA-222 after OmniAb completed key discovery work, moving the program into its ...
VERAXA Biotech AG has appointed Christoph Erkel, Ph.D., as chief scientific officer to lead the development of its BiTAC platform technologies for sol...
NanoViricides raises $3.8 million through a registered direct offering with a single institutional investor, providing funding for its clinical-stage ...
VERAXA Biotech AG appoints Christoph Erkel as CSO to lead development of its BiTAC platform for solid tumor therapies, succeeding Rick Austin after a ...
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE development strategy, reducing regulatory unc...
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on development strategy ...
Siegfried appoints Eduardo Montanha as Chief Operating Officer to lead its combined Drug Substances and Drug Products operations, enhancing end-to-end...
NextPlat Corp acquires an independent pharmacy near Pensacola, Florida, for $1.5 million to expand PharmcoRx into an underserved rural market, introdu...
Onco-Innovations Limited finalized the analytical reference standard for its lead oncology candidate ONC010, strengthening its CMC framework and progr...
VERAXA Biotech has selected ATUM to develop stable clonal cell lines for its lead BiTAC T-cell engager, a crucial step toward IND/CTA-enabling studies...
The sustained release polymers market is projected to grow from $3.8 billion in 2026 to $7.8 billion by 2036 at a 7.4% CAGR, driven by rising chronic ...
VERAXA Biotech AG reports progress in its BiTAC platform with four T-cell engager programs and a partnering strategy to monetize non-BiTAC assets, pos...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager program through a collaboration with ATUM, aiming to improve tumor se...
The article highlights the strong deal activity in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, emphasizing how VERAXA Biote...
Ace Therapeutics announces end-to-end preclinical services for analgesic drug development, featuring diverse validated in vivo pain models and a compl...
